News Features Year in Review: DAPA-HF Tops Heart Failure News Amid Other Wins and Losses Shelley Wood December 23, 2019
News Conference News AHA 2019 Sex Differences, EF Thresholds Probed for Sacubitril/Valsartan in Heart Failure Shelley Wood November 22, 2019
News Conference News AHA 2019 Dapagliflozin Has Benefits Across Heart Failure Subgroups Todd Neale November 17, 2019
News Daily News ARB Use Linked to Suicide in New Study, but Is the Finding Real? Michael O'Riordan October 18, 2019
News Conference News HFSA 2019 New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF L.A. McKeown September 18, 2019
News Daily News High-Sensitivity Troponin T May Offer Glimpse Into Future HF Risk: ARIC Analysis L.A. McKeown September 13, 2019
News Conference News ESC 2019 DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics Shelley Wood September 01, 2019
News Conference News ESC 2019 PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen Todd Neale September 01, 2019
News Conference News ESC 2019 ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More Shelley Wood August 22, 2019
News Conference News ACC 2019 PIONEER-HF Extension Study Further Supports Starting Sacubitril/Valsartan in the Hospital Michael O'Riordan March 25, 2019
News Daily News FDA Provides Update on Tainted ARB Investigation, With New Impurity Found Todd Neale March 04, 2019
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for December 2018 Caitlin E. Cox January 01, 2019